REMAP-CAP is flexible: you can choose the domain(s) and interventions (minimum of 2 per domain) you want
to participate in as a site. Each domain is available in one or both of two strata: Non‐pandemic CAP and Pandemic.
Last updated on 25-03-2024
Severe disease state is defined as patients who receive organ failure support in an ICU.
Moderate disease state is defined as:
ANTIBIOTICS | Non-pandemic CAP | Pandemic |
---|---|---|
A.1 – Ceftriaxone + Macrolide | ||
A.2 – Moxifloxacin or Levofloxacin | ||
A.3 – Piperacillin‐Tazobactam + Macrolide | ||
A.4 – Amoxicillin‐Clavulanate + Macrolide |
Macrolide Duration | Non-pandemic CAP | Pandemic |
---|---|---|
M.1 – Standard course macrolide | ||
M.2 – Extended course macrolide |
Corticosteroid | Non-pandemic CAP | Pandemic |
---|---|---|
C.1 – No corticosteroid | ||
C.3 – Shock‐dependent hydrocortisone | ||
C.4 – Fixed‐course dexamethasone |
Influenza Antiviral | Non-pandemic CAP | Pandemic |
---|---|---|
I.1 – No antiviral for influenza | ||
I.2 – Oseltamivir 5 days | ||
I.3 – Oseltamivir 10 days | ||
I.4 – Baloxavir on days 1 and 4 | ||
I.5 – 5 days Oseltamivir + Baloxavir on days 1 & 4 | ||
I.6 – 10 days Oseltamivir + Baloxavir on days 1 & 4 |
Immunoglobulin | Non-pandemic CAP | Pandemic |
---|---|---|
P.1 – No immunoglobulin for COVID‐19 | ||
P.2 – High‐titer convalescent plasma |
Mechanical Ventilation | Non-pandemic CAP | Pandemic |
---|---|---|
V.1 – Clinician‐preferred ventilation strategy | ||
V.2 – Protocolized ventilation strategy |
Endothelial Modulation | Non-pandemic CAP | Pandemic |
---|---|---|
E.1 – No endothelial modulator | ||
E.2 – Enteral imatinib |
* UK only.
Influenza Immune Modulation | Non-pandemic CAP | Pandemic |
---|---|---|
No immune modulation (no placebo) | ||
Tocilizumab | ||
Baricitinib |
University Medical Center Utrecht
Heidelberglaan 100
3584 CX Utrecht
The Netherlands
Email:
EU.remapcap@umcutrecht.nl
REMAP-CAP ClinicalTrials.gov registration NCT02735707
REMAP-CAP EU Clinical Trials Register EUCT number: 2023-507889-89
REMAP-CAP is supported by the ECRAID-Base project which has received funding from the EU Horizon 2020 research and innovation programme (grant number 965313).
Inseparable to the design of this trial, platform conclusions are generated through frequent adaptive analyses as data accrues. To date, REMAP-CAP has contributed to the knowledge about the best treatment of COVID-19 with several results:
ACE2 RAS DOMAIN (27 Feb 2022)
Antiplatelet DOMAIN (23 Jun 2021)
CORTICOSTEROID DOMAIN
COVID-19 IMMUNE MODULATION DOMAIN
COVID-19 ANTI-COAGULATION DOMAIN
COVID-19 IMMUNOGLOBULIN DOMAIN
COVID-19 ANTIVIRAL DOMAIN